38 results on '"T. Takenouchi"'
Search Results
2. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
- Author
-
Yokota K, Takenouchi T, Fujisawa Y, Fukushima S, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Han S, Watanabe M, Noguchi K, and Yamazaki N
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Follow-Up Studies, Adult, Japan, Neoplasm Staging, Aged, 80 and over, Treatment Outcome, East Asian People, Melanoma drug therapy, Melanoma mortality, Melanoma pathology, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Skin Neoplasms mortality, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological administration & dosage
- Abstract
Pembrolizumab demonstrated an acceptable safety profile and promising antitumor activity in Japanese patients with advanced melanoma in the phase 1b KEYNOTE-041 (Study of Pembrolizumab [MK-3475] in Participants With Advanced Melanoma) trial. To evaluate the long-term efficacy and safety of pembrolizumab in Japanese patients with advanced melanoma in KEYNOTE-041. The current analysis reports results of additional follow-up of approximately 12 months since the initial analysis. Eligible patients had locally advanced (unresectable stage III) or metastatic (stage IV) melanoma not amenable to local therapy and had received two or fewer prior systemic therapies. Pembrolizumab 2 mg/kg was given every 3 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Primary end points included safety, tolerability, and overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by independent central review. The data cutoff for this analysis was August 30, 2017. Forty-two patients were followed up for a median of 22.3 months (range, 2.63-30.82 months). The ORR was 24.3% (nine of 37 evaluable patients [95% confidence interval (CI), 11.8%-41.2%]). Two patients with partial response at the time of the initial analysis achieved complete response. The median overall survival (OS) was 25.1 months (95% CI, 13.1-not reached] and the 30-month OS rate was 46.3% (95% CI, 29.8%-61.3%). The median duration of response was not reached. Treatment-related adverse events (TRAEs) were reported in 78.6% of patients; the incidence of grade 3 to 5 TRAEs was 23.8%. No additional treatment-related deaths occurred since the initial analysis. Pembrolizumab provided durable antitumor activity and an acceptable safety profile in Japanese patients with advanced melanoma., (© 2024 MSD K.K. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)
- Published
- 2024
- Full Text
- View/download PDF
3. Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases.
- Author
-
Fujisawa Y, Namikawa K, Yoshino K, Kiniwa Y, Ito T, Kato H, Matsushita S, Hoashi T, Nakamura Y, Yoshikawa S, Miyagawa T, Asai J, Matsuya T, Fukushima S, Kato J, Takenouchi T, Uchi H, Masuzawa M, Yanagi T, and Maekawa T
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, East Asian People, Ipilimumab therapeutic use, Nivolumab therapeutic use, Retrospective Studies, Melanoma drug therapy, Melanoma etiology, Skin Neoplasms drug therapy, Skin Neoplasms etiology
- Abstract
Competing Interests: Conflicts of interest see Appendix S2.
- Published
- 2023
- Full Text
- View/download PDF
4. Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study.
- Author
-
Inozume T, Namikawa K, Kato H, Yoshikawa S, Kiniwa Y, Yoshino K, Mizuhashi S, Ito T, Takenouchi T, Matsushita S, Fujisawa Y, Matsuzawa T, Sugihara S, Asai J, Kitagawa H, Maekawa T, Isei T, Yasuda M, Yamazaki N, Uhara H, and Nakamura Y
- Subjects
- Humans, CTLA-4 Antigen genetics, East Asian People, Immune Checkpoint Inhibitors therapeutic use, Proto-Oncogene Proteins B-raf genetics, Retrospective Studies, Melanoma, Cutaneous Malignant, Melanoma drug therapy, Melanoma genetics, Skin Neoplasms drug therapy, Skin Neoplasms genetics
- Abstract
Background: Efficacy of anti-PD-1 antibody monotherapy (PD1) or anti-PD-1 plus anti-CTLA-4 combination therapy (PD1 +CTLA4) for melanoma is affected by its clinical subtype. The amount of tumor mutation burden (TMB) caused by cumulative sun damage (CSD) is occasionally used to explain this; however, their relationship in Japanese nonacral cutaneous melanoma (NACM) is still unclear., Objective: To analyze the ICI efficacy and its relationship with CSD of the primary lesion in Japanese patients with NACM., Methods: Japanese patients with advanced BRAF wild-type NACM who received first-line ICIs were recruited. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), and the degree of solar elastosis (SE) were evaluated., Results: A total of 146 patients (PD1 group 113 and PD1 +CTLA4 group 33) were included. No significant differences in ORR were observed between the PD1 and PD1 +CTLA4 groups (35 % vs. 36 %; P = 0.67) or PFS and OS (median PFS 6.1 months vs. 8.5 months; P = 0.46, median OS 28.1 months vs. not reached; P = 0.59). Multivariate survival analysis revealed that PD1 +CTLA4 did not prolong the PFS and OS. The SE score had no effect on either PFS or OS., Conclusions: ICI efficacy was not as high as those reported in Western countries, and PD1 +CTLA4 did not present better clinical efficacy compared to PD1. Indicators of CSD did not serve as a predictor for clinical advantage. These findings may partially support the theory that ICI efficacy is affected by CSD; however, other unrecognized factors may also exist., Competing Interests: Conflict of interest Takashi Inozume has received honoraria from Bristol-Myers Squibb (BMS), Ono Pharma, and MSD. Kenjiro Namikawa has served as a consultant or/and has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Hiroshi Kato has received honoraria from Novartis and Ono Pharma. Shusuke Yoshikawa has received honoraria from Novartis and Ono Pharma. Yukiko Kiniwa has received honoraria from Novartis and Ono Pharma. Tatsuya Takenouchi has received honoraria BMS, MSD, Novartis, and Ono Pharma. Shigeto Matsushita has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Yasuhiro Fujisawa received honoraria from BMS, MSD, Novartis, Ono Pharma, and Eizai. Takeo Maekawa has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Taiki Isei has served as a consultant or/and has received honoraria from Ono, Pfizer, BMS, and Novartis Pharma. Masahito Yasuda received honoraria from Novartis. Naoya Yamazaki receives institutional research funding from BMS, MSD, Novartis, Ono, and Takara Bio, and has served as consultant or/and has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Hisashi Uhara received honoraria from BMS, MSD, Novartis, Ono Pharma, Taiho, Sun Pharma, Mitsubishi Tanabe Pharma, Janssen Pharma, Kyowa Hakko Kirin, and Merck Biopharma Co. Yasuhiro Nakamura has served as a consultant or/and has received honoraria from MSD, Novartis, BMS, Maruho, Ono Pharma, Taisho Toyama, and Taiho Pharma. The other authors have no conflicts of interest to disclose., (Copyright © 2023 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
5. Diagnostic accuracy of dermoscopy for 934 basal cell carcinomas: A single-center retrospective study.
- Author
-
Yuki A, Takatsuka S, Abe R, and Takenouchi T
- Subjects
- Humans, Retrospective Studies, Dermoscopy, Skin Neoplasms diagnostic imaging, Skin Neoplasms pathology, Carcinoma, Basal Cell diagnostic imaging, Carcinoma, Basal Cell pathology, Keratosis, Seborrheic diagnostic imaging
- Abstract
Although the efficacy of dermoscopic diagnosis of basal cell carcinoma (BCC) has already been established, most studies have been conducted in Western countries. However, there are racial differences in the clinicopathological characteristics of BCC, highlighting the need for a survey among Asians. Herein, we aimed to investigate the diagnostic accuracy of dermoscopy in 934 Japanese patients with BCC and statistically analyze the clinicopathological factors affecting diagnostic accuracy. We analyzed 5093 skin lesions, including 934 BCCs that were diagnosed consecutively from 1998 to 2018. The sensitivity and specificity of dermoscopic diagnosis for BCC were calculated. The sensitivity and specificity of dermoscopic diagnosis were 92.2% and 96.0%, respectively. There were 73 false-negative cases of BCCs that were clinically diagnosed with other diseases. The most common incorrect clinical diagnosis was seborrheic keratosis (n = 18), followed by melanocytic nevus (n = 15). Multiple logistic regression analysis showed that sensitivity was significantly lower in BCCs located on the trunk and extremities, which showed low pigmentation (less than 10% of the lesion surface) and were diagnosed by a resident dermatologist. Experience of 3-6 months of 12 resident dermatologists revealed increased sensitivity. Dermoscopy is a reliable tool for the accurate diagnosis of BCC in Japanese individuals. Care should be taken when diagnosing BCCs of the trunk and extremities, and the less-pigmented subtype because of lower sensitivity. A certain amount of experience is required to improve the skills for dermoscopy., (© 2022 Japanese Dermatological Association.)
- Published
- 2023
- Full Text
- View/download PDF
6. Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).
- Author
-
Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, Uchi H, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, and Yamazaki N
- Subjects
- Humans, Japan, Judgment, Margins of Excision, Carcinoma, Basal Cell pathology, Carcinoma, Basal Cell surgery, Head and Neck Neoplasms, Skin Neoplasms diagnosis, Skin Neoplasms pathology, Skin Neoplasms surgery
- Abstract
Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists' concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80-100%, 60-79%, and 51-59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82-89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use., (© 2022 Japanese Dermatological Association.)
- Published
- 2022
- Full Text
- View/download PDF
7. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.
- Author
-
Yamazaki N, Isei T, Kiyohara Y, Koga H, Kojima T, Takenouchi T, Yokota K, Namikawa K, Yi M, Keegan A, and Fukushima S
- Subjects
- Adult, Female, Herpesvirus 1, Human, Humans, Japan, Male, Biological Products adverse effects, Melanoma drug therapy, Melanoma pathology, Oncolytic Virotherapy adverse effects, Skin Neoplasms drug therapy, Skin Neoplasms pathology
- Abstract
Talimogene laherparepvec (T-VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open-label, dose de-escalation study evaluated the safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV melanoma. Eligible adult patients had histologically confirmed stage IIIB-IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had ≥1 injectable lesion, serum lactate dehydrogenase ≤1.5x upper limit of normal, ECOG performance status of 0 or 1, and adequate hematologic, hepatic, and renal function. T-VEC was injected intralesionally (first dose, ≤4.0 ml of 10
6 PFU/ml; after 3 weeks and then every 2 weeks thereafter, ≤4.0 ml of 108 PFU/ml). Primary endpoints were dose-limiting toxicities (DLTs) and durable response rate (DRR). Of 18 enrolled patients (72.2% female), 16 had received ≥1 prior line of therapy. Ten patients discontinued T-VEC due to disease progression. Median (range) follow-up was 20.0 (4-37) months. No DLTs were observed; 17 (94.4%) patients had treatment-emergent adverse events (AEs). Fourteen (77.8%) patients had treatment-related AEs; the most frequent were pyrexia (44.4%), malaise (16.7%), chills, decreased appetite, pruritus, and skin ulcer (11.1% each). The primary efficacy endpoint was met: 2 (11.1%) patients had a durable partial response ≥6 months. The DRR was consistent with that observed in a phase III trial of T-VEC in non-Asian patients. The safety profile was consistent with the patients' underlying disease and the known safety profile of T-VEC., (© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2022
- Full Text
- View/download PDF
8. Natural course of pediatric longitudinal melanonychia: A retrospective cohort study in Japan.
- Author
-
Matsui Y, Sasaki J, Takatsuka S, and Takenouchi T
- Subjects
- Child, Humans, Japan, Retrospective Studies, Nail Diseases diagnosis, Nail Diseases epidemiology, Nevus, Pigmented, Skin Neoplasms diagnosis, Skin Neoplasms epidemiology
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2022
- Full Text
- View/download PDF
9. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
- Author
-
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, and Yamazaki N
- Subjects
- Aged, CTLA-4 Antigen, Humans, Immunotherapy methods, Japan, Retrospective Studies, Melanoma drug therapy, Skin Neoplasms
- Abstract
Background: Anti-programmed cell death protein 1 (PD-1) antibody monotherapy (PD1) has led to favorable responses in advanced non-acral cutaneous melanoma among Caucasian populations; however, recent studies suggest that this therapy has limited efficacy in mucosal melanoma (MCM). Thus, advanced MCM patients are candidates for PD1 plus anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) combination therapy (PD1 + CTLA4). Data on the efficacy of immunotherapy in MCM, however, are limited. We aimed to compare the efficacies of PD1 and PD1 + CTLA4 in Japanese advanced MCM patients., Patients and Methods: We retrospectively assessed advanced MCM patients treated with PD1 or PD1 + CTLA4 at 24 Japanese institutions. Patient baseline characteristics, clinical responses (RECIST), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier analysis, and toxicity was assessed to estimate the efficacy and safety of PD1 and PD1 + CTLA4., Results: Altogether, 329 patients with advanced MCM were included in this study. PD1 and PD1 + CTLA4 were used in 263 and 66 patients, respectively. Baseline characteristics were similar between both treatment groups, except for age (median age 71 versus 65 years; P < 0.001). No significant differences were observed between the PD1 and PD1 + CTLA4 groups with respect to objective response rate (26% versus 29%; P = 0.26) or PFS and OS (median PFS 5.9 months versus 6.8 months; P = 0.55, median OS 20.4 months versus 20.1 months; P = 0.55). Cox multivariate survival analysis revealed that PD1 + CTLA4 did not prolong PFS and OS (PFS: hazard ratio 0.83, 95% confidence interval 0.58-1.19, P = 0.30; OS: HR 0.89, 95% confidence interval 0.57-1.38, P = 0.59). The rate of ≥grade 3 immune-related adverse events was higher in the PD1 + CTLA4 group than in the PD1 group (53% versus 17%; P < 0.001)., Conclusions: First-line PD1 + CTLA4 demonstrated comparable clinical efficacy to PD1 in Japanese MCM patients, but with a higher rate of immune-related adverse events., Competing Interests: Disclosure YN receives institutional research funding from Kaken, Ono Pharma, Pola Pharma, and Torii, and has served as a consultant and/or has received honoraria from Bristol Myers Squibb (BMS), Maruho, Merck Sharp & Dohme (MSD), Novartis, Ono Pharma, Taisho Toyama, and Taiho Pharma. KN has served as a consultant and/or has received honoraria from BMS, MSD, Novartis, and Ono Pharma. SY has received honoraria from Novartis and Ono Pharma. YK has received honoraria from Novartis and Ono Pharma. TM has received honoraria from BMS, MSD, Novartis, and Ono Pharma. OY has received research funding and/or honoraria from Ono Pharma. TI has served as a consultant and/or has received honoraria from Ono Pharma, Pfizer, BMS, and Novartis Pharma. SM has received honoraria from Ono Pharma. SF has received research funding from Ono Pharma. SS has received honoraria from Ono Pharma. TT has received honoraria from BMS, MSD, Novartis, and Ono Pharma. HK has received honoraria from Novartis and Ono Pharma. AO has served as a consultant and/or has received honoraria from BMS, MSD, Novartis, and Ono Pharma and received research funding from Eisai. TI has received honoraria from BMS, MSD, and Ono Pharma. YU has received honoraria from Ono and Novartis Pharma. YT has received honoraria from BMS, Maruho, MSD, Novartis, and Ono Pharma. NY receives institutional research funding from BMS, MSD, Novartis, Ono, Takara Bio, Amgen, and Merck Biopharma, and has served as consultant and/or has received honoraria from BMS, MSD, Novartis, and Ono Pharma. The other authors have declared no conflicts of interest., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study).
- Author
-
Yamazaki N, Takenouchi T, Nakamura Y, Takahashi A, Namikawa K, Kitano S, Fujita T, Kubota K, Yamanaka T, and Kawakami Y
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological therapeutic use, Female, Humans, Japan epidemiology, Male, Middle Aged, Prospective Studies, Young Adult, Melanoma drug therapy, Nivolumab therapeutic use, Skin Neoplasms drug therapy
- Abstract
Background: Nivolumab, the anti-programmed cell death protein 1 antibody, has been approved for advanced melanoma, mainly based on evidence from Western countries. The profile of melanoma differs between Caucasian and Asian patients. This study was performed to obtain post-marketing data of nivolumab in Japanese patients with advanced melanoma., Methods: This prospective, observational study involved patients with unresectable or metastatic melanoma treated with nivolumab at dosages of 2 mg/kg every 3 weeks or 3 mg/kg every 2 weeks. The primary endpoints were objective response rate and overall survival. The secondary endpoints were progression-free survival and the objective response rate according to immune-related Response Evaluation Criteria in Solid Tumours., Result: Among 124 patients analysed, mucosal melanoma was the most common subtype, followed by acral lentiginous, nodular, superficial spreading and lentigo maligna melanoma. Response Evaluation Criteria in Solid Tumours evaluation showed an objective response rate of 17.7%. The median survival time was 15.93 months, and the 1-year overall survival rate was 66%. Outcomes were not significantly different among melanoma subtypes. Better overall survival and/or progression-free survival but not objective response rate were associated with performance status 0, lower levels of lactate dehydrogenase, C-reactive protein and neutrophil-to-lymphocyte ratio. Patients with immune-related adverse events showed a better objective response rate, 3-month landmark overall survival and progression-free survival than patients without immune-related adverse events., Conclusion: The objective response rate and median survival time in Japanese patients treated with nivolumab were lower in daily practice than the >30% and >30 months, respectively, seen in global phase III trials. The occurrence of immune-related adverse events may be a predictor for survival and response to treatment with nivolumab., (© The Author(s) 2021. Published by Oxford University Press.)
- Published
- 2021
- Full Text
- View/download PDF
11. Observation policy for sentinel node metastasis of melanoma: Comparative study with completion lymph node dissection in Japanese patients.
- Author
-
Matsui Y, Sasaki J, Takatsuka S, and Takenouchi T
- Subjects
- Humans, Japan, Lymph Node Excision, Neoplasm Recurrence, Local, Policy, Retrospective Studies, Sentinel Lymph Node Biopsy, Melanoma surgery, Sentinel Lymph Node surgery, Skin Neoplasms surgery
- Abstract
Based on the results of international multicenter randomized trials, completion lymph node dissection for patients with sentinel lymph node-positive melanoma is no longer routinely recommended. However, clinicians should take into consideration racial and medical resource differences when applying this evidence to clinical practice in Japan. To evaluate the clinical validity of the observation policy of omitting completion lymph node dissection, we retrospectively surveyed patients with sentinel lymph node-positive melanoma between 2002 and 2020 at Niigata Cancer Center Hospital. A total of 59 patients were categorized into the observation group (n = 19) and completion lymph node dissection group (n = 40). Newly developed anticancer agents, including targeted therapy and immunotherapy, were more commonly used in the observation group than in the completion lymph node dissection group as either adjuvant therapy (31.6% vs. 5.0%) or post-recurrence therapy (100% vs. 34.8%). The median overall survival in the observation group (not reached) was significantly longer than that in the completion lymph node dissection group (95.0 months; p = 0.02), which was mainly attributed to the difference in post-recurrence overall survival. There was no significant difference in recurrence-free survival between the two groups (p = 0.63). Although the use of new anticancer agents leads to bias, this study demonstrates that observation without prompt completion lymph node dissection provides a favorable overall survival without increasing the risk of recurrence compared with completion lymph node dissection. The observation policy for patients with sentinel lymph node-positive melanoma patients is considered to be clinically valid in real-world medical practice., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
12. Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
- Author
-
Uhara H, Kiyohara Y, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, Uchi H, Fukushima S, Minami H, Hatsumichi M, and Yamazaki N
- Subjects
- Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Humans, Ipilimumab therapeutic use, Japan epidemiology, Nivolumab adverse effects, Progression-Free Survival, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan. Twenty-four patients with treatment-naïve, recurrent, or unresectable stage III/IV malignant melanoma received 3 mg/kg nivolumab every 2 weeks until progressive disease or unacceptable toxicity occurred. The 5-year overall survival (OS) rate was 26.1%. Five years after the start of nivolumab treatment, there were six survivors. The 5-year OS rate was 66.7% for patients with a superficial spreading type, 14.3% for acral lentiginous type, and 16.7% for mucosal type. The 5-year progression-free survival rate was 17.2%. No new cases of partial response or complete response were observed after 3 years, and overall response and disease control rates were similar to those reported at 3 years. The treatment-related adverse events reported between the 3- and 5-year follow-up periods were anemia (grade 2), white blood cell count decrease (grade 2), and psoriasiform dermatitis (grade 2) in one patient each. No new grade 3 or higher treatment-related adverse events occurred in this period. In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in confirmed long-term survival. No new safety signals were reported in the studied population., (© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
13. Risk factors for lymph node metastasis in cutaneous squamous cell carcinoma: a long-term retrospective study of Japanese patients.
- Author
-
Saito Y, Fujikawa H, Takatsuka S, Abe R, and Takenouchi T
- Subjects
- Female, Humans, Japan, Lymph Nodes pathology, Lymphatic Metastasis, Neoplasm Staging, Prognosis, Retrospective Studies, Risk Factors, Carcinoma, Squamous Cell pathology, Skin Neoplasms pathology
- Abstract
Background: Cutaneous squamous cell carcinoma (CSCC) is one of the most common skin cancers. Prognosis is favorable following surgical resection of early-stage disease, but the management of the metastatic disease is challenging. Several prognostic risk factors have been described in the American Joint Committee on Cancer/the Union for International Cancer Control (UICC) 8th edition staging and the Brigham and Women's Hospital T classification system. However, their clinical validity in Asian populations is unclear because of racial differences in the clinical characteristics of CSCC. This study aimed to identify factors that could predict lymph node metastasis in Asian patients., Methods: This retrospective single-center study evaluated 540 patients with primary CSCC between 1989 and 2013. Five factors were evaluated for their ability to predict lymph node metastasis: maximum tumor diameter, tumor thickness, depth of invasion, degree of differentiation, and infiltrative growth pattern (INF)., Results: Tumor diameter > 2 cm (p < 0.0001), tumor thickness > 6 mm (p < 0.0001), invasion beyond the subcutaneous fat (p < 0.0001), poor differentiation (p = 0.042), and INFc infiltration (p < 0.0001) were associated with lymph node metastasis in the univariate analyses. In the multivariate analysis, lymph node metastasis was independently associated with tumor size > 2 cm [hazard ratio (HR) 2.9, 95% confidence interval (CI) 1.4-6.2; p = 0.006], tumor thickness > 6.0 mm (HR 2.9, 95% CI 1.3-6.4; p = 0.007), and invasion beyond the subcutaneous fat (HR 2.3, 95% CI 1.0-5.1; p = 0.045)., Conclusion: Larger tumor diameter, greater tumor thickness, and deeper invasion included in the UICC T classification system are associated with increased risks of lymph node metastasis from CSCC in Japanese patients.
- Published
- 2021
- Full Text
- View/download PDF
14. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).
- Author
-
Ishii M, Hirai I, Tanese K, Fusumae T, Nakamura Y, Fukuda K, Uchi H, Kabashima K, Otsuka A, Yokota K, Yamazaki N, Namikawa K, Fujimura T, Takenouchi T, Yamamoto Y, Nishiguchi M, Sato Y, Amagai M, and Funakoshi T
- Subjects
- Adult, Female, Humans, Male, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Epithelial Cells drug effects, Epithelial Cells pathology, Japan, Neoplasm Staging, Response Evaluation Criteria in Solid Tumors, Clinical Trials, Phase II as Topic, Multicenter Studies as Topic, Carcinoma, Basal Cell drug therapy, Carcinoma, Basal Cell pathology, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Neoplasms, Adnexal and Skin Appendage drug therapy, Neoplasms, Adnexal and Skin Appendage pathology, Nivolumab administration & dosage, Nivolumab adverse effects, Programmed Cell Death 1 Receptor antagonists & inhibitors, Skin Neoplasms drug therapy, Skin Neoplasms pathology
- Abstract
Introduction: Malignant cutaneous epithelial tumors comprise various skin malignancies originating from the cutaneous epithelium, including cutaneous squamous cell carcinoma, basal cell carcinoma, and malignant cutaneous adnexal tumors. Treatment options are limited, as the rarity of these tumors, especially among Asians, renders well-controlled clinical trials extremely challenging to conduct. Thus, we designed a clinical trial to evaluate the efficacy and safety of the anti-programmed cell death-1 (PD-1) monoclonal antibody nivolumab in patients with metastatic cutaneous squamous cell carcinomas and other rare metastatic cutaneous epithelial tumors., Methods and Analysis: This is an open-label, single-arm, multicenter, phase 2 clinical trial involving patients with metastatic malignant cutaneous epithelial tumors. Nivolumab (480 mg) will be administered intravenously every 4 weeks for a maximum of 26 doses. The primary outcome of the study will be the response rate based on response evaluation criteria in solid tumors, version 1.1. Assuming a null hypothesis of a response rate ≤5% and an alternative hypothesis of a 25% response rate, a minimum of 26 patients are required to achieve a 5% two-sided type I error and 80% power based on the exact binomial distribution. Finally, a target cohort size of 30 patients was determined as some patient dropout will be expected., Discussion: This is the first phase 2 clinical trial evaluating the efficacy and safety of the PD-1 inhibitor nivolumab in Asian patients with metastatic malignant cutaneous epithelial tumors. The findings of the study will contribute to the development of novel treatment approaches for patients with rare cutaneous malignancies, which remains an unmet clinical need., Trial Registration: Registry number: jRCT 2031190048.
- Published
- 2020
- Full Text
- View/download PDF
15. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
- Author
-
Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, Isei T, Hayashi T, Shibayama Y, and Yamazaki N
- Subjects
- Humans, Japan, Programmed Cell Death 1 Receptor, Retrospective Studies, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Background: Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the efficacy of anti-programmed cell death 1 (anti-PD-1) antibodies in advanced AM., Patients and Methods: We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective response rate (ORR, RECIST), survival estimated using Kaplan-Meier analysis, and toxicity (Common Terminology Criteria for Adverse Events 4.0.) were analyzed to estimate the efficacy of the anti-PD-1 antibodies., Results: In total, 193 patients (nail apparatus, 70; palm and sole, 123) were included in the study. Anti-PD-1 antibody was used as first-line therapy in 143 patients (74.1%). Baseline lactate dehydrogenase (LDH) was within the normal concentration in 102 patients (52.8%). The ORR of all patients was 16.6% (complete response, 3.1%; partial response, 13.5%), and the median overall survival (OS) was 18.1 months. Normal LDH concentrations showed a significantly stronger association with better OS than abnormal concentrations (median OS 24.9 versus 10.7 months; P < 0.001). Although baseline characteristics were similar between the nail apparatus and the palm and sole groups, ORR was significantly lower in the nail apparatus group [6/70 patients (8.6%) versus 26/123 patients (21.1%); P = 0.026]. Moreover, the median OS in this group was significantly poorer (12.8 versus 22.3 months; P = 0.03)., Conclusions: Anti-PD-1 antibodies have limited efficacy in AM patients. Notably, patients with nail apparatus melanoma had poorer response and survival, making nail apparatus melanoma a strong candidate for further research on the efficacy of novel combination therapies with immune checkpoint inhibitors., Competing Interests: Disclosure YN has served as an advisor/consultant to MSD and Novartis and has received honoraria from Bristol-Myers Squibb, Maruho, MSD, Novartis, Ono Pharmaceutical, Taiho Pharmaceutical, and Taisho Toyama Pharma. KN has served as an advisor/consultant to Bristol-Myers Squibb, MSD, Novartis, and Ono Pharmaceutical, and has received honoraria from Bristol-Myers Squibb, Eisai, MSD, Novartis, Ono Pharmaceutical, Pharma International, Takara Bio, and Toray Industries. KY has served as an advisor/consultant to Brystol-Myers-Squibb, Novartis, and Ono Pharmaceutical, and has received honoraria from Bristol-Myers Squibb, Novartis, and Ono Pharmaceutical. SY has served as an advisor/consultant to Novartis and has received honoraria from Bristol-Myers Squibb, MSD, Novartis, and Ono Pharmaceutical. HU has received honoraria from Bristol-Myers Squibb, Novartis, and Ono Pharmaceutical. YN has received honoraria from Ono Pharmaceutical. SF receives institutional research funding from Brystol-Myers-Squibb, MSD, and Ono Pharmaceutical, and has received honoraria from MSD and Ono Pharmaceutical. TT has received honoraria from Bristol-Myers Squibb, MSD, Novartis, and Ono Pharmaceutical. HU receives institutional research funding from Abbvie, Daiichi Synkyo, Eisai, Kaken Pharmaceutical, Kyowa Hakko Kirin, Maruho, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co. Ltd., Nihonkayaku, Ono Pharmaceutical, Pola Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and Tsumura & Co, has served as an advisor/consultant to Bristol-Myers Squibb, Chugai Pharma, Kyowa Hakko Kirin, MSD, Novartis, and Ono Pharmaceutical, and has received honoraria from Bristol-Myers Squibb, Chugai Pharma, Maruho, MSD, Novartis, Ono Pharmaceutical, Pola Pharma, Janssen China R&D, Kyowa Hakko Kirin, and Mitsubishi Tanabe Pharma. TF receives institutional research funding from MSD, Ono Pharmaceutical, and Zenyaku Kogyo, and has received honoraria from Bristol-Myers Squibb, Minophagen Pharmaceuticals, MSD, Novartis, and Ono Pharmaceutical. YT has received honoraria from Bristol-Myers Squibb, Maruho, and Ono Pharmaceutical. AO receives institutional research funding from Bristol-Myers Squibb and Ono Pharmaceutical and has received honoraria from Bristol-Myers Squibb and Ono Pharmaceutical. SM has received honoraria from Bristol-Myers Squibb, Kyowa Hakko Kirin, MSD, and Ono Pharmaceutical. TI has received honoraria from Bristol-Myers Squibb, MSD, Novartis, and Ono Pharmaceutical. NY receives institutional research funding from Bristol-Myers Squibb, MSD, Novartis, Ono Pharmaceutical, and Takara Bio, and has received honoraria from Bristol-Myers Squibb, MSD, Novartis, and Ono Pharmaceutical. None of these entities had any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. All remaining authors have declared no conflicts of interest., (Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
16. Hereditary spastic paraplegia masqueraded by congenital melanocytic nevus syndrome: Dual pathogenesis of germline non-mosaicism and somatic mosaicism.
- Author
-
Sakaguchi Y, Uehara T, Sasaki M, Fujimura K, Kishi K, Kosaki K, and Takenouchi T
- Subjects
- Child, Female, Humans, Mosaicism, Mutation, GTP Phosphohydrolases genetics, Membrane Proteins genetics, Nevus, Pigmented genetics, Skin Neoplasms genetics, Spastic Paraplegia, Hereditary genetics, Spastin genetics
- Abstract
Neurocutaneous disorders are caused by germline and/or somatic mutations and involve the integument and central nervous systems. Congenital melanocytic nevus syndrome is characterized by melanotic skin lesions caused by somatic mutations at codon 61 in NRAS. A large cutaneous lesion raises the risk of central nervous system involvement. We report an 8-year-old girl with a congenital giant pigmented nevus that covered almost her entire back. Despite the absence of any radiological evidence of intracranial melanosis, the patient exhibited progressive limb spasticity with preserved intellectual ability. An extensive genetic analysis identified a specific class of heterozygous germline mutation in SPAST, p.(Arg499His), which is responsible for hereditary spastic paraplegia with infantile onset. In addition, a known heterozygous somatic mutation in NRAS, p.(Gln61Lys) was detected in the cutaneous lesion. This observation recapitulates concomitant mosaicism and non-mosaicism within a single individual and suggests that the possibility of a dual genetic diagnosis should be considered when neurological decline is observed in a patient with a neurocutaneous disorder without any detectable intracranial lesions., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used.
- Author
-
Ogata D, Namikawa K, Otsuka M, Asai J, Kato H, Yasuda M, Maekawa T, Fujimura T, Kato J, Takenouchi T, Nagase K, Kawaguchi M, Kaji T, Kuwatsuka Y, Shibayama Y, Takai T, Okumura M, Kambayashi Y, Yoshikawa S, Yamazaki N, and Tsuchida T
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Skin Neoplasms pathology, Skin Neoplasms therapy, Survival Rate, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell mortality, Chemoradiotherapy mortality, Cisplatin therapeutic use, Radiotherapy mortality, Skin Neoplasms mortality
- Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Few patients with cSCC experience metastases, but the prognosis of advanced cSCC (acSCC) is dismal. Evidence regarding systemic therapy for acSCC is limited. Therefore, we aimed to determine the most effective systemic treatment for acSCC., Patients and Methods: This retrospective study involved 16 Japanese institutions. We documented patient and tumour characteristics and disease course of patients with acSCC who received systemic therapy between 1st January 2006 and 31st December 2015. We compared the overall survival (OS) and progression-free survival (PFS) for (1) platinum versus non-platinum groups, (2) radiation plus chemotherapy first-line therapy (RCT) versus non-RCT groups and (3) platinum-based RCT versus non-platinum-based RCT groups., Results: Although the use of platinum-based systemic therapy was not associated with statistically significant improvements in PFS and OS, there were significant differences between the RCT and non-RCT groups (PFS: p < 0.001, OS: p = 0.003). In the subgroup analysis, RCT significantly prolonged PFS and OS in the nodal SCC (nSCC) group. For the RCT and non-RCT groups, the median OS was 110 and 14 months, respectively, and the 5-year OS rate was 54% and 21%, respectively., Conclusion: RCT could improve OS in patients with nSCC. However, further multicenter prospective studies are needed to establish evidence for superiority of RCT., Competing Interests: Conflict of interest statement The authors have no conflict of interest to declare., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
- Author
-
Yokota K, Uchi H, Uhara H, Yoshikawa S, Takenouchi T, Inozume T, Ozawa K, Ihn H, Fujisawa Y, Qureshi A, de Pril V, Otsuka Y, Weber J, and Yamazaki N
- Subjects
- Adult, Aged, Aged, 80 and over, Asian People, Chemotherapy, Adjuvant, Female, Humans, Male, Middle Aged, Young Adult, Antineoplastic Agents, Immunological therapeutic use, Ipilimumab therapeutic use, Melanoma drug therapy, Nivolumab therapeutic use, Skin Neoplasms drug therapy
- Abstract
The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19-2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence., (© 2019 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)
- Published
- 2019
- Full Text
- View/download PDF
19. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
- Author
-
Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, Uchi H, Ihn H, Hatsumichi M, and Minami H
- Subjects
- Administration, Intravenous, Aged, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological therapeutic use, Asian People, Follow-Up Studies, Humans, Japan, Kaplan-Meier Estimate, Male, Melanoma ethnology, Melanoma pathology, Middle Aged, Neoplasm Recurrence, Local, Nivolumab administration & dosage, Nivolumab adverse effects, Pruritus chemically induced, Skin Neoplasms ethnology, Skin Neoplasms pathology, Vitiligo chemically induced, Melanoma, Cutaneous Malignant, Melanoma drug therapy, Nivolumab therapeutic use, Skin Neoplasms drug therapy
- Abstract
The immune checkpoint inhibitor nivolumab inhibits the programmed death 1 receptor and suppresses the immune resistance of cancer cells. This is a long-term follow up of a single-arm, open-label, multicenter, phase II study of nivolumab in untreated Japanese patients with stage III/IV or recurrent melanoma. In addition, a post-hoc subgroup analysis stratified by melanoma types was performed. Nivolumab was administered intravenously at a dose of 3 mg/kg every 2 weeks. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), best overall response, the disease control rate and change in tumor diameter. Safety was assessed by recording treatment-related adverse events (TRAE), including select immune-related adverse events. Of the 24 patients initially included in the primary phase II study, 10 survived for over 3 years (41.7%). The ORR was 34.8% (90% confidence interval [CI]: 20.8, 51.9) for all patients. When analyzing by melanoma type, the ORR was 66.7% (90% CI: 34.7, 88.3) for superficial spreading, 33.3% (90% CI: 11.7, 65.3) for mucosal, and 28.6% (90% CI: 10.0, 59.1) for acral lentiginous tumors. The median OS was 32.9 months, the 3-year OS rate was 43.5%, and the 3-year PFS rate was 17.2%. A long-term response was observed in all the tumor types. The most common TRAE included skin toxicity (45.8%) and endocrine disorders (29.2%). This study demonstrated the long-term efficacy and tolerability of nivolumab in patients with advanced or recurrent melanoma, irrespective of melanoma type., (© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2019
- Full Text
- View/download PDF
20. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.
- Author
-
Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, and Katoh N
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Asian People, Child, Child, Preschool, Female, Humans, Japan epidemiology, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Young Adult, Melanoma mortality, Melanoma pathology, Skin Neoplasms mortality, Skin Neoplasms pathology
- Abstract
Background: The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large-scale Asian studies that include follow-up data have been reported., Objectives: To investigate the clinical characteristics of Japanese patients with melanoma and to evaluate the prognostic factors., Methods: Detailed patient information was collected from the database of Japanese Melanoma Study Group of the Japanese Skin Cancer Society. The American Joint Committee on Cancer seventh Edition system was used for TNM classification. The Kaplan-Meier method and Cox proportional hazards model were used to estimate the impact of clinical and histological parameters on disease-specific survival in patients with invasive melanoma., Results: In total, 4594 patients were included in this analysis. The most common clinical type was acral lentiginous melanoma (40.4%) followed by superficial spreading melanoma (20.5%), nodular melanoma (10.0%), mucosal melanoma (9.5%), and lentigo maligna melanoma (8.1%). The 5-year disease-specific survival for each stage was as follows: IA = 98.0%, IB = 93.9%, IIA = 94.8%, IIB = 82.4%, IIC = 71.8%, IIIA = 75.0%, IIIB = 61.3%, IIIC = 41.7%, and IV = 17.7%. Although multivariate analysis showed that clinical classifications were not associated with survival across all stages, acral type was an independent poor prognostic factor in stage IIIA., Conclusions: Our study revealed the characteristics of melanoma in the Japanese population. The 5-year disease-specific survival of each stage showed a similar trend to that of Caucasians. While clinical classification was not associated with survival in any stages, acral type was associated with poor survival in stage IIIA. Our result might indicate the aggressiveness of acral type in certain populations., (© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
21. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
- Author
-
Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, and Katoh N
- Subjects
- Chemotherapy, Adjuvant methods, Cohort Studies, Databases, Factual statistics & numerical data, Disease-Free Survival, Humans, Japan epidemiology, Kaplan-Meier Estimate, Melanoma drug therapy, Melanoma mortality, Neoplasm Recurrence, Local prevention & control, Neoplasm Staging, Prognosis, Skin Neoplasms drug therapy, Skin Neoplasms mortality, Antineoplastic Agents therapeutic use, Lymphatic Metastasis therapy, Melanoma diagnosis, Neoplasm Recurrence, Local epidemiology, Skin Neoplasms diagnosis
- Abstract
Background: The American Joint Committee on Cancer (AJCC) 8
th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population., Objective: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients., Methods: The AJCC 7th and 8th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8th staging were selected. The Kaplan-Meier method was used to estimate disease-specific survival and relapse-free survival., Results: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7th and 8th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7th and 8th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%., Conclusion: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7th and 8th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8th Edition staging were completely different from the 7th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively., (Copyright © 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
22. Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).
- Author
-
Namikawa K, Tsutsumida A, Mizutani T, Shibata T, Takenouchi T, Yoshikawa S, Kiyohara Y, Uchi H, Furue M, Ogata D, Tsuchida T, and Yamazaki N
- Subjects
- Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival, Humans, Japan, Patient Selection, Treatment Outcome, Melanoma, Cutaneous Malignant, Interferon-beta therapeutic use, Medical Oncology, Melanoma drug therapy, Melanoma surgery, Skin Neoplasms drug therapy, Skin Neoplasms surgery
- Abstract
The Dermatologic Oncology Group of Japan Clinical Oncology Group has started a randomized phase III trial to confirm the superiority of adjuvant therapy with locoregional interferon beta in overall survival over surgery alone for patients with pathological stage II/III cutaneous melanoma (JCOG1309). Patients in the interferon beta arm receive intra- or subcutaneous injections of interferon beta directly into the surgical site at a flat dose of 3 million units once per day. Treatment is repeated for 10 consecutive days every 8 weeks for a total of 3 courses during the induction phase, then 1-day injection every 4 weeks for 2.5 years. A total of 240 patients will be accrued from 17 Japanese institutions within 6.5 years. Primary endpoint is overall survival. Secondary endpoints are relapse-free survival, distant metastasis-free survival, pattern of recurrence, and adverse events. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000017494 [http://www.umin.ac.jp/ctr/index.htm]., (© The Author 2017. Published by Oxford University Press.)
- Published
- 2017
- Full Text
- View/download PDF
23. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
- Author
-
Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, and Yokota K
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents adverse effects, Asian People, Disease-Free Survival, Female, Humans, Male, Melanoma genetics, Melanoma pathology, Middle Aged, Skin pathology, Skin Neoplasms genetics, Skin Neoplasms pathology, Survival Analysis, Melanoma, Cutaneous Malignant, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Melanoma drug therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor immunology, Skin Neoplasms drug therapy
- Abstract
Purpose: This phase I b study evaluated the safety and anti-tumor activity of pembrolizumab in Japanese patients with advanced melanoma., Methods: Pembrolizumab (2 mg/kg) was given every 3 weeks (Q3W) for up to 2 years or until confirmed progression or unacceptable toxicity. The tumor response was assessed as per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by both investigator review and central review., Results: Forty-two patients with advanced melanoma received pembrolizumab. A primary cutaneous histology was observed in 34 patients (81.0%), while a primary mucosal histology was observed in 8 patients (19.0%). Thirty-four patients (81.0%) experienced treatment-related adverse events (AEs). The most common treatment-related AEs were pruritus, maculopapular rash, malaise, and hypothyroidism. Grade 3-5 treatment-related AEs occurred in 8 patients (19.0%). The only grade 3-5 treatment-related AE reported in at least two patients was anemia. There were two treatment-related deaths (unknown cause and cerebral hemorrhage). Among the 37 evaluable patients, the confirmed overall response rates (ORRs) determined by central review were 24.1% (95% CI 10.3-43.5) for cutaneous melanoma and 25.0% (95% CI 3.2-65.1) for mucosal melanoma. The responses were durable, and the median duration of response was not reached in either population. The median overall survival (OS) was not reached, with a 12-month OS of 82.7% for cutaneous melanoma and 51.4% for mucosal melanoma., Conclusion: The safety profile of pembrolizumab in Japanese patients was similar to that reported in the previous clinical studies. Pembrolizumab provided promising anti-tumor activity in Japanese patients with advanced melanoma.
- Published
- 2017
- Full Text
- View/download PDF
24. Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.
- Author
-
Tsutsumida A, Takahashi A, Namikawa K, Yamazaki N, Uhara H, Teramoto Y, Takenouchi T, Fukushima S, Yokota K, Uehara J, Matsushita S, Shibayama Y, Hatta N, Masui Y, Uchi H, Fujisawa Y, and Ogata D
- Subjects
- Adult, Aged, Aged, 80 and over, Axilla, Female, Humans, Incidence, Japan epidemiology, Lymphatic Metastasis diagnosis, Male, Melanoma epidemiology, Middle Aged, Neoplasm Staging, Retrospective Studies, Skin Neoplasms epidemiology, Treatment Outcome, Lymph Node Excision, Melanoma pathology, Melanoma surgery, Sentinel Lymph Node pathology, Sentinel Lymph Node Biopsy, Skin Neoplasms pathology, Skin Neoplasms surgery
- Abstract
Background: Axillary lymph node dissection (ALND) has been recommended to include levels I-III for melanoma patients who have evidence of metastasis in the axillary sentinel lymph node (SLN). The extent of the subsequent axillary dissection is in debate. The objective of this study was to determine the frequency of metastasis of level III nodes in addition to that of level II nodes in this setting., Methods: A multi-institutional retrospective study was undertaken in 14 melanoma treatment centers in Japan., Results: Between 2007 and 2012, 69 patients with involved axillary SLNs underwent a subsequent ALND and 55 underwent level I and II dissections. Level III metastatic nodes, which is our primary endpoint, were seen in only 1 patient (1.5 %). The level II metastatic rate was 4.4 %., Conclusions: Our study sample size was small, but melanoma patients with positive SLN rarely had level III disease, suggesting that level III dissection may be unnecessary. We also found that level II metastasis was not so frequent. More evidence is needed to standardize the extent of ALND and to identify the patients who would have the most benefit with undergoing level II dissection for positive axillary SLNs.
- Published
- 2016
- Full Text
- View/download PDF
25. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
- Author
-
Sakaizawa K, Ashida A, Uchiyama A, Ito T, Fujisawa Y, Ogata D, Matsushita S, Fujii K, Fukushima S, Shibayama Y, Hatta N, Takenouchi T, Uehara J, Okuyama R, Yamazaki N, and Uhara H
- Subjects
- Aged, Asian People genetics, Female, Humans, Japan, Male, Melanoma pathology, Middle Aged, Skin pathology, Skin Neoplasms pathology, GTP Phosphohydrolases genetics, Melanoma genetics, Membrane Proteins genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins c-kit genetics, Skin Neoplasms genetics
- Abstract
Background: The importance of the genetic background of melanoma cells to the individual susceptibility to treatment has become apparent. In Caucasians, BRAF mutations are frequently detected in lesions on the skin of younger patients compared to NRAS and KIT mutations. However, clinical and pathological characteristics associated with BRAF, NRAS and KIT mutations have not been fully evaluated in East Asians., Objective: To clarify clinical and pathological characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients., Methods: Clinical data were retrospectively collected from 11 hospitals in Japan. BRAF, NRAS and KIT mutations were evaluated with polymerase chain reaction and Sanger sequencing. The relationships between these gene mutations and pathological and clinical findings were analyzed., Results: The number of cases examined was 171 (primary: 135, metastases: 11, paired: 25), and all were Japanese patients. The detection rates of BRAF, NRAS and KIT mutations were 30.4%, 12.3% and 12.9%, respectively. Compared with the wild type, the presence of BRAF mutations was significantly associated with younger age (median, 50.0 years vs. 70.0 years, p<0.001). BRAF mutation was frequently detected in the lesions of the scalp (80%; 4/5), trunk (72.0%; 18/25), extremities (56.7%; 17/30) and neck (44.4%; 4/9), and the least prevalent were the face (22.2%; 2/9), nail (12.5%; 3/24), palm or sole (8.9%; 4/45) and mucosa (0%). NRAS mutations were prevalent in the face (33.3%) and palm or sole (20.0%), and the median age of these patients was 70.5 years. A KIT mutation was observed in the nail apparatus (25%), palm or sole (15.6%) and mucosa (18.2%). The median age of the patients with a KIT mutation was 63.0 years. Heterogeneity of mutations between primary and metastatic lesions was detected in six of 25 cases (24%). Solar elastosis was identified in 12 of 71 cases (15.3%), among which four cases harbored BRAF(V600E) (2 cases), BRAF(V600K), NRAS(Q61K) or NRAS(Q61L), respectively., Conclusion: Some clinical characteristics associated with BRAF, NRAS and KIT mutations were observed in Japanese patients, and we observed both similarities to and differences from those of Caucasians. Our findings could provide useful information in efforts to clarify the tumor genesis of malignant melanomas., (Copyright © 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
26. The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients.
- Author
-
Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, Uhara H, Hatta N, Uchi H, Matsushita S, Takenouchi T, Hayashi T, Fujimoto M, and Ohara K
- Subjects
- Aged, Blood Vessels pathology, Female, Humans, Lymph Nodes surgery, Lymphatic Diseases pathology, Lymphatic Metastasis, Lymphatic Vessels pathology, Male, Neoplasm Invasiveness, Paget Disease, Extramammary pathology, Paget Disease, Extramammary surgery, Retrospective Studies, Skin Neoplasms surgery, Survival Rate, Lymph Node Excision, Lymph Nodes pathology, Paget Disease, Extramammary secondary, Sentinel Lymph Node Biopsy, Skin Neoplasms pathology
- Abstract
Background: Although extramammary Paget's disease (EMPD) mostly presents as intraepithelial carcinoma, we sometimes encounter patients with invasive EMPD (iEMPD) who have lymph node metastasis and may develop distant metastasis. Although sentinel lymph node biopsy (SLNB) is widely accepted for various cancers, there is no large study that has assessed its role in iEMPD., Objective: The main objective of this study is to assess the role of SLNB in patients with iEMPD., Materials and Methods: We retrospectively collected data on 151 iEMPD patients treated from 1998 to 2012 in 11 institutes in Japan. All 151 patients received curative surgery for their primary tumor and none of them had distant metastasis. SLNB was performed on the 107 patients without lymphadenopathy to determine their LN status. The 44 other patients with lymphadenopathy underwent one of the following procedures to determine their LN status: SLNB in 22 cases, immediate LN dissection in 21, and LN biopsy in 1., Results: Compared to those without lymphadenopathy, patients with lymphadenopathy had advanced primary tumors (nodule in the primary tumor, thicker tumor, deeper invasion level, and lymphovascular invasion). The rate of LN metastasis in patients with lymphadenopathy was 80%, compared to 15% in patients without lymphadenopathy who underwent SLNB. Compared to those with negative SLN, patients with positive SLN had advanced primary tumors (nodule in the primary tumor, deeper invasion level, and lymphovascular invasion). Multivariate analysis revealed that dermal invasion (odds ratio 5.8, p=0.04) and lymphovascular invasion (odds ratio 18.0, p=0.0023) were independent factors associated with SLN positivity. Notably, there was no difference in survival between patients with or without SLN metastasis (p=0.71). On the other hand, patients with lymphadenopathy showed worse survival than those with positive SLN (p=0.045)., Conclusion: Clinical lymphadenopathy was strongly correlated with pathological LN metastasis and also associated with worse survival than absence of lymphadenopathy. The rate of occult LN metastasis detected by SLNB was 15%. Survival was not affected by SLN status even when an advanced primary tumor was present in patients with positive SLN. Our results raise the possibility that SLNB and subsequent LN dissection improved the survival of patients with early stage lymphatic spread. Our study indicates that SLNB should be considered for iEMPD if lymphadenopathy is not apparent., (Copyright © 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
27. Long-term prognosis after surgical excision of basal cell carcinoma: a single institutional study in Japan.
- Author
-
Takenouchi T and Takatsuka S
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Basal Cell epidemiology, Carcinoma, Basal Cell pathology, Female, Humans, Japan epidemiology, Male, Middle Aged, Neoplasm Recurrence, Local epidemiology, Prognosis, Retrospective Studies, Skin pathology, Skin Neoplasms epidemiology, Skin Neoplasms pathology, Carcinoma, Basal Cell surgery, Skin Neoplasms surgery
- Abstract
Conventional surgical excision (SE) is commonly used to treat patients with basal cell carcinoma (BCC). There have been few studies, however, evaluating the long-term prognosis of Japanese patients receiving SE for treatment of BCC. The purpose of this retrospective study is to determine the effectiveness of SE in accomplishing the long-term cure of patients with BCC. We enrolled 290 patients with primary BCC who underwent SE during 1998-2006. The prognosis of treated patients was subsequently investigated using data obtained through our hospital cancer registration section. In total, 205 patients (70.7%) were treated for BCC lesions located on the face. The mean tumor diameter of excised lesions was 12.8 mm. A majority of patients in the study (256 patients, 88.3%) had pigmented BCC. The mean surgical margin at SE was 3.8 mm. Two patients developed local recurrence during the postoperative course of 290 patients (mean duration, 80 months). One patient developed recurrent disease 21 months after surgery, and the other developed recurrence at 66 months after surgery. The 5- and 10-year cumulative recurrence rates were 0.4% and 0.8%, respectively. In conclusion, this study demonstrated that long-term high cure rates of BCC in Japanese patients may be achieved through conventional SE. A better prognosis was obtained in this study compared with similar studies reported previously in Caucasians. This may be related to the predominance of pigmented versus non-pigmented lesions in the Japanese population., (© 2013 Japanese Dermatological Association.)
- Published
- 2013
- Full Text
- View/download PDF
28. The prevalence of Merkel cell polyomavirus in Japanese patients with Merkel cell carcinoma.
- Author
-
Hattori T, Takeuchi Y, Takenouchi T, Hirofuji A, Tsuchida T, Kabumoto T, Fujiwara H, Ito M, Shimizu A, Okada E, Motegi S, Tamura A, and Ishikawa O
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Basal Cell ethnology, Carcinoma, Basal Cell virology, Carcinoma, Merkel Cell ethnology, Carcinoma, Squamous Cell ethnology, Carcinoma, Squamous Cell virology, Case-Control Studies, DNA, Viral blood, Female, Humans, Japan, Male, Merkel cell polyomavirus genetics, Middle Aged, Phylogeny, Polyomavirus Infections ethnology, Prevalence, Retrospective Studies, Skin Neoplasms ethnology, Tumor Virus Infections ethnology, Viral Load genetics, Asian People, Carcinoma, Merkel Cell virology, Merkel cell polyomavirus isolation & purification, Polyomavirus Infections epidemiology, Skin Neoplasms virology, Tumor Virus Infections epidemiology
- Abstract
Background: A novel polyomavirus, the Merkel cell polyomavirus (MCPyV) has been implicated in the pathogenesis of Merkel cell carcinoma (MCC); however, the prevalence of MCPyV in Japan has not been extensively investigated., Objective: To clarify the prevalence of MCPyV in Japanese patients with MCC., Methods: MCPyV DNA was examined by polymerase chain reaction (PCR) in formalin-fixed paraffin-embedded (FFPE) or frozen tissue samples from 26 patients with MCC diagnosed in four medical centers in Japan. Immunohistochemistry was simultaneously performed using a monoclonal antibody against the viral large T (LT) antigen. FFPE samples from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were also analyzed as controls., Results: Twenty-three out of 26 cases (88.5%) were positive for MCPyV DNA by PCR. The amplified products harbored 4 patterns of mutations. Phylogenetic analysis demonstrated that one of our strains was closely related to the other Japanese strains previously reported. The LT antigen was expressed in various degrees in 20 of 26 cases (76.9%) by immunohistochemistry. Histological type had little relation to CM2B4 positivity, whereas 3 of 5 trabecular-type tumors showed no staining. The immunoreactivity for CM2B4 did not correlate with the relative viral DNA load. In BCC and SCC, the LT antigen was immunohistochemically positive, but MCPyV DNA was not detected by PCR. The cells around some MCC and non-MCC tumors were stained with CM2B4 with a distribution similar to CD20- and CD45RO- (especially CD8-) positive lymphocytes., Conclusion: MCPyV was highly positive in Japanese patients with MCC. It is of note that the positive rate differs depending upon the detection method., (Copyright © 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
29. Applicability of radiocolloids, blue dyes and fluorescent indocyanine green to sentinel node biopsy in melanoma.
- Author
-
Uhara H, Yamazaki N, Takata M, Inoue Y, Sakakibara A, Nakamura Y, Suehiro K, Yamamoto A, Kamo R, Mochida K, Takenaka H, Yamashita T, Takenouchi T, Yoshikawa S, Takahashi A, Uehara J, Kawai M, Iwata H, Kadono T, Kai Y, Watanabe S, Murata S, Ikeda T, Fukamizu H, Tanaka T, Hatta N, and Saida T
- Subjects
- Coloring Agents, Fluorescent Dyes, Head and Neck Neoplasms, Humans, Indocyanine Green, Melanoma diagnosis, Melanoma diagnostic imaging, Organotechnetium Compounds, Phytic Acid, Radionuclide Imaging, Radiopharmaceuticals, Rosaniline Dyes, Technetium, Technetium Compounds, Tin Compounds, Lymphatic Metastasis diagnosis, Lymphatic Metastasis diagnostic imaging, Melanoma secondary, Sentinel Lymph Node Biopsy methods, Skin Neoplasms
- Abstract
Patients with primary cutaneous melanoma underwent sentinel node (SN) mapping and biopsy at 25 facilities in Japan by the combination of radiocolloid with gamma probe and dye. Technetium-99m ((99m)Tc)-tin colloid, (99m)Tc-phytate, 2% patent blue violet (PBV) and 0.4% indigo carmine were used as tracers. In some hospitals, 0.5% fluorescent indocyanine green, which allows visualization of the SN with an infrared camera, was concomitantly used and examined. A total of 673 patients were enrolled, and 562 cases were eligible. The detection rates of SN were 95.5% (147/154) with the combination of tin colloid and PBV, 98.9% (368/372) with the combination of phytate and PBV, and 97.2% (35/36) with the combination of tin colloid or phytate and indigo carmine. SN was not detected in 12 cases by the combination method, and the primary tumor was in the head and neck in six of those 12 cases. In eight of 526 cases (1.5%), SN was detected by PBV but not by radiocolloid. There were 13 cases (2.5%) in which SN was detected by radiocolloid but not by PBV. In 18 of 36 cases (50%), SN was detected by radiocolloid but not by indigo carmine. Concomitantly used fluorescent indocyanine green detected SN in all of 67 cases. Interference with transcutaneous oximetry by PVB was observed in some cases, although it caused no clinical trouble. Allergic reactions were not reported with any of the tracers. (99m)Tc-tin colloid, (99m)Tc-phytate, PBV and indocyanine green are useful tracers for SN mapping., (© 2011 Japanese Dermatological Association.)
- Published
- 2012
- Full Text
- View/download PDF
30. Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan.
- Author
-
Namikawa K, Yamazaki N, Nakai Y, Ihn H, Tomita Y, Uhara H, Takenouchi T, Kiyohara Y, Moroi Y, Yamamoto Y, Otsuka F, Kamiya H, Iizuka H, Hatta N, and Kadono T
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Japan, Lymphatic Metastasis, Male, Melanoma mortality, Melanoma surgery, Middle Aged, Predictive Value of Tests, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Skin Neoplasms surgery, Survival Rate, Young Adult, Melanoma secondary, Neoplasm Micrometastasis pathology, Skin Neoplasms mortality, Skin Neoplasms pathology
- Abstract
Various microscopic classifications of metastatic sentinel lymph nodes (SLN) have been reported along with predictors of additional lymph node positivity and their correlations with the prognosis. The purpose of this study was to re-evaluate these classifications in the Japanese population. We selected the following three classifications, based on the procedural simplicity of the measurements: maximum diameter (maximum diameter of the largest tumor lesion in the SLN; <0.1, 0.1-1.0, >1.0 mm), invasion depth (depth of tumor invasion measured from the capsule in the SLN; SI ≤ 0.3 mm, SII >0.3 to ≤ 1.0 mm, SIII >1.0 mm), and microanatomic location (microanatomic location of the tumor deposits within the SLN; "subcapsular", "parenchymal", "combined", "multifocal", "extensive"). A retrospective study, using prescribed survey forms, was carried out. Among the 450 patients, including the 149 cases with SLN metastasis, an additional lymph node positivity rate of 0% could be predicted only in patients with a maximum diameter category of less than 0.1 mm. As compared with that in the SLN metastasis-negative cases, however, the prognosis was poorer in cases with SLN metastasis, even those with lesions falling under the maximum diameter category of less than 0.1 mm, invasion depth category of SI (≤ 0.3 mm) and microanatomic location category of subcapsular. The prognosis is particularly poor for the microanatomic location category of extensive, which should thus be regarded as a macrometastasis. A prospective study with standardized procedures, including pathological evaluation, is needed in order to confirm our conclusion., (© 2011 Japanese Dermatological Association.)
- Published
- 2012
- Full Text
- View/download PDF
31. Key points in dermoscopic diagnosis of basal cell carcinoma and seborrheic keratosis in Japanese.
- Author
-
Takenouchi T
- Subjects
- Asian People, Epidermal Cyst diagnosis, Humans, Sensitivity and Specificity, Carcinoma, Basal Cell diagnosis, Dermoscopy methods, Keratosis, Seborrheic diagnosis, Skin Neoplasms diagnosis
- Abstract
Basal cell carcinoma (BCC) and seborrheic keratosis (SK) are representative pigmented skin tumors, and they are differentiated as non-melanocytic lesions in the two-step dermoscopy algorithm proposed by the Consensus Net Meeting on Dermoscopy. Because most BCC in Japanese patients are pigmented clinically, dermoscopy plays an important role in their differential diagnosis. The dermoscopic criteria for BCC include the lack of a pigment network and the presence of at least one positive feature for BCC, such as large blue-gray ovoid nests, multiple blue-gray globules, leaf-like areas, spoke wheel areas, arborizing vessels and ulceration. Whereas various dermoscopic features are seen in SK, comedo-like openings, milia-like cysts, and fissures and ridges are especially important features. It is necessary for clinicians to consider the pathological conditions causing the dermoscopic features of BCC and SK. In addition, the sensitivity and specificity of each feature should be taken into consideration to ensure an accurate dermoscopic diagnosis., (© 2010 Japanese Dermatological Association.)
- Published
- 2011
- Full Text
- View/download PDF
32. [Diagnosis and treatment for squamous cell carcinoma and basal cell carcinoma of skin].
- Author
-
Takenouchi T
- Subjects
- Biopsy, Carcinoma, Basal Cell classification, Carcinoma, Basal Cell surgery, Carcinoma, Squamous Cell classification, Carcinoma, Squamous Cell surgery, Dermoscopy, Humans, Lymphatic Metastasis pathology, Neoplasm Staging, Prognosis, Skin Neoplasms classification, Skin Neoplasms surgery, Carcinoma, Basal Cell diagnosis, Carcinoma, Basal Cell therapy, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell therapy, Skin Neoplasms diagnosis, Skin Neoplasms therapy
- Published
- 2008
33. [Basal cell carcinoma].
- Author
-
Takenouchi T
- Subjects
- Aminoquinolines therapeutic use, Antineoplastic Agents therapeutic use, Combined Modality Therapy, Humans, Imiquimod, Mohs Surgery, Photochemotherapy, Photosensitizing Agents, Carcinoma, Basal Cell drug therapy, Carcinoma, Basal Cell surgery, Carcinoma, Basal Cell therapy, Skin Neoplasms drug therapy, Skin Neoplasms surgery, Skin Neoplasms therapy
- Abstract
Basal cell carcinoma (BCC) is the most common skin cancer. It tends to be locally invasive but rarely metastasizes. Dermoscopy has been reported as a useful in vivo method for the accurate clinical diagnosis of BCC. The first-line treatment for BCC is surgical excision, however, clinical trials of non-surgical treatment modalities such as topical imiquimod and photodynamic therapy have recently been published in the English literature, and are gradually being introduced into Japan. Although clinical practice guidelines for the management of BCC have been already published in several countries, original guidelines for Japan are required in light of clinical and ethnic differences.
- Published
- 2006
34. Factors influencing the linear depth of invasion of primary basal cell carcinoma.
- Author
-
Takenouchi T, Nomoto S, and Ito M
- Subjects
- Aged, Carcinoma, Basal Cell surgery, Female, Humans, Linear Models, Male, Neoplasm Invasiveness, Retrospective Studies, Skin Neoplasms surgery, Carcinoma, Basal Cell pathology, Skin Neoplasms pathology
- Abstract
Background: Predicting subclinical growth of basal cell carcinoma (BCC) is important for clinicians to determine adequate surgical margins. However, few attempts to predict the depth of invasion of BCC prior to surgery have been done., Objective: To identify the factors significantly influencing the depth of invasion of primary BCC., Methods: In 235 primary BCCs treated with surgical excision, maximum vertical diameter, designated as "invasion index," from the surrounding skin surface to the bottom of the tumor was measured. Multiple linear regression analysis was used to identify the factors significantly influencing the invasion index. Seven variables including age, sex, duration, anatomic location, tumor horizontal diameter, histologic subtypes, and ulceration were entered into the model., Results: Among seven variables, male sex (P = 0.0003), larger tumor diameter (P = 0.0011), and histologic subtypes including infiltrative, morpheic, and micronodular subtypes (P = 0.0019) had significant strength of influence for the invasion index., Conclusion: The three predictive factors positively related to the linear depth of invasion in this study are important, but not sufficient, considerations at planning of surgery and for postoperative follow-up of BCC.
- Published
- 2001
- Full Text
- View/download PDF
35. A case of localized follicular hamartoma: an ultrastructural and immunohistochemical study.
- Author
-
Morohashi M, Sakamoto F, Takenouchi T, Hashimoto T, Tago O, and Ito M
- Subjects
- Adult, Biomarkers, Tumor analysis, Female, Hamartoma chemistry, Humans, Immunoenzyme Techniques, Melanocytes ultrastructure, Melanosomes ultrastructure, Merkel Cells ultrastructure, Neoplasm Proteins analysis, Skin Neoplasms chemistry, Hair Follicle ultrastructure, Hamartoma ultrastructure, Skin Neoplasms ultrastructure
- Abstract
We report the case of a 22-year-old woman with a nevoid plaque that we termed localized follicular hamartoma. The plaque was noticed at puberty on a unilateral site of the face and scalp. Clinically, it revealed numerous, skin-colored to light brown papules alone and in groups, occasionally bearing a single hair. Histologically, branched epithelial nests of squamoid and/or basaloid cells were revealed in connection with the interfollicular epidermis and the upper portions of hair follicles, of which the lower portions showed normal structures. Immunohistochemically, the epithelial nests showed the keratin expression consisted with that of the infundibular epithelium. S-100-positive cells were found in the epithelial nests and the stroma. Factor XIIIa-positive dendritic cells were numerous in adjacent to the epithelial nests. Ultrastructurally, immature melanocytes with a small number of premelanosomes and Merkel cells were found in the nests. Stromal dendritic cells showed the adherent features of the cytoplasmic processes to anchoring fibrils or basal lamina of the epithelial nests. From these findings, our case is a hamartoma, which seems to be an abortive growth of secondary hair germs with a limited differentiation to the upper follicular portion.
- Published
- 2000
- Full Text
- View/download PDF
36. Establishment and characterization of a clear-cell sarcoma (malignant melanoma of soft parts) cell line.
- Author
-
Takenouchi T, Ito K, Kazama T, and Ito M
- Subjects
- Adult, Animals, Cell Line, Humans, Karyotyping, Male, Mice, Mice, Nude, Microscopy, Electron, Neoplasm Transplantation, Sarcoma, Clear Cell ultrastructure, Skin Neoplasms ultrastructure, Tumor Cells, Cultured, Sarcoma, Clear Cell pathology, Skin Neoplasms pathology
- Abstract
A clear cell sarcoma (CCS) cell line, designated as NCS-1, was established in monolayer culture from a xenograft line originating from a metastatic CCS. Marked karyotypic aberrations and tumorigenicity in nude mice revealed the malignant derivation of the NCS-1 cell line. These cells contained abundant glycogen and were amelanotic by light microscopy. By electron microscopy, however, melanosomes in various developmental stages were seen, and some of them were partially melanized. The electron microscopic dopa reaction revealed the presence of tyrosinase activity. Enzyme-linked immunoadsorbent assay revealed that NCS-1 cells expressed a 75-kDa glycoprotein which was identified as a marker of highly differentiated melanoma cells. From these results, NCS-1 cells were found to retain both cytochemical and morphological properties of CCS. Application of NCS-1 cells to a panel of monoclonal antibodies recognizing melanocytic differentiation antigens showed that they corresponded approximately to highly differentiated melanoma cells. In conclusion, the present study strongly supports the close relationship between CCS and malignant melanoma.
- Published
- 1994
- Full Text
- View/download PDF
37. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
- Author
-
Y. Nakamura, K. Namikawa, K. Yoshino, S. Yoshikawa, H. Uchi, K. Goto, S. Fukushima, Y. Kiniwa, T. Takenouchi, H. Uhara, T. Kawai, N. Hatta, T. Funakoshi, Y. Teramoto, A. Otsuka, H. Doi, D. Ogata, S. Matsushita, T. Isei, T. Hayashi, Y. Shibayama, and N. Yamazaki
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Skin Neoplasms ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Pembrolizumab ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Internal medicine ,medicine ,Humans ,Stage (cooking) ,Melanoma ,Retrospective Studies ,business.industry ,Common Terminology Criteria for Adverse Events ,Hematology ,Immunotherapy ,medicine.disease ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,Toxicity ,Nivolumab ,business - Abstract
Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the efficacy of anti-programmed cell death 1 (anti-PD-1) antibodies in advanced AM.We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective response rate (ORR, RECIST), survival estimated using Kaplan-Meier analysis, and toxicity (Common Terminology Criteria for Adverse Events 4.0.) were analyzed to estimate the efficacy of the anti-PD-1 antibodies.In total, 193 patients (nail apparatus, 70; palm and sole, 123) were included in the study. Anti-PD-1 antibody was used as first-line therapy in 143 patients (74.1%). Baseline lactate dehydrogenase (LDH) was within the normal concentration in 102 patients (52.8%). The ORR of all patients was 16.6% (complete response, 3.1%; partial response, 13.5%), and the median overall survival (OS) was 18.1 months. Normal LDH concentrations showed a significantly stronger association with better OS than abnormal concentrations (median OS 24.9 versus 10.7 months; P0.001). Although baseline characteristics were similar between the nail apparatus and the palm and sole groups, ORR was significantly lower in the nail apparatus group [6/70 patients (8.6%) versus 26/123 patients (21.1%); P = 0.026]. Moreover, the median OS in this group was significantly poorer (12.8 versus 22.3 months; P = 0.03).Anti-PD-1 antibodies have limited efficacy in AM patients. Notably, patients with nail apparatus melanoma had poorer response and survival, making nail apparatus melanoma a strong candidate for further research on the efficacy of novel combination therapies with immune checkpoint inhibitors.
- Published
- 2020
38. A case of localized follicular hamartoma: an ultrastructural and immunohistochemical study
- Author
-
Masaaki Morohashi, Masahiro Ito, Fumiko Sakamoto, T. Hashimoto, T. Takenouchi, and O. Tago
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Histology ,Stromal cell ,Hamartoma ,Dermatology ,Biology ,Merkel Cells ,Pathology and Forensic Medicine ,Immunoenzyme Techniques ,Keratin ,Anchoring fibrils ,Biomarkers, Tumor ,medicine ,Humans ,chemistry.chemical_classification ,Melanosomes ,integumentary system ,Anatomy ,medicine.disease ,Hair follicle ,Neoplasm Proteins ,medicine.anatomical_structure ,chemistry ,Ultrastructure ,Melanocytes ,Female ,Basal lamina ,Merkel cell ,Hair Follicle - Abstract
We report the case of a 22-year-old woman with a nevoid plaque that we termed localized follicular hamartoma. The plaque was noticed at puberty on a unilateral site of the face and scalp. Clinically, it revealed numerous, skin-colored to light brown papules alone and in groups, occasionally bearing a single hair. Histologically, branched epithelial nests of squamoid and/or basaloid cells were revealed in connection with the interfollicular epidermis and the upper portions of hair follicles, of which the lower portions showed normal structures. Immunohistochemically, the epithelial nests showed the keratin expression consisted with that of the infundibular epithelium. S-100-positive cells were found in the epithelial nests and the stroma. Factor XIIIa-positive dendritic cells were numerous in adjacent to the epithelial nests. Ultrastructurally, immature melanocytes with a small number of premelanosomes and Merkel cells were found in the nests. Stromal dendritic cells showed the adherent features of the cytoplasmic processes to anchoring fibrils or basal lamina of the epithelial nests. From these findings, our case is a hamartoma, which seems to be an abortive growth of secondary hair germs with a limited differentiation to the upper follicular portion.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.